Description

Cenderitide (CAS 507289-11-4) is a first-in-class chimeric natriuretic peptide engineered by fusing C-type natriuretic peptide (CNP) with the C-terminal segment of Dendroaspis natriuretic peptide (DNP) . This design enables potent coactivation of particulate guanylyl cyclase receptors pGC-A and pGC-B, combining the renal-enhancing and diuretic effects of DNP with the anti-fibrotic and antiproliferative functions of CNP.

Preclinical canine studies show that Cenderitide markedly stimulates cGMP, induces natriuresis, diuresis, and increases GFR, while exerting less blood pressure reduction than BNP. Importantly, in human stable heart failure subjects, a 4-hour infusion of Cenderitide was safe, well-tolerated, raised plasma and urine cGMP levels, and did not alter blood pressure. These data support its potential as a heart failure research tool and therapeutic candidate.

Produced under GMP-compliant conditions, Cenderitide is supplied as a lyophilized peptide at 99.84% purity, ensuring batch consistency and robust research performance.

Product Specifications

Mechanism of Action & Research Applications

Mechanism of Action

Cenderitide simultaneously activates pGC-A (via DNP C-terminus) and pGC-B (via CNP backbone), leading to elevated intracellular cGMP. This dual receptor targeting confers natriuretic, diuretic, renal-enhancing, anti-fibrotic, and antiproliferative effects, while minimizing hypotension compared to other NPs. Additionally, it demonstrates resistance to neprilysin degradation, enhancing in vivo stability.

Research Applications

• Heart Failure Models: Evaluate diuretic and antifibrotic responses, preserving GFR without excessive BP drop.

• Cardiorenal Physiology: Study cGMP-mediated pathways in cardiac and renal tissues, especially in preclinical canine models and human trials.

• Drug Combination Studies: Use with diuretics to enhance natriuresis and preload reduction without hypotension BioMed Central.

• Fibrosis & Remodeling: Assess suppression of TGF-?–induced collagen synthesis and impact on cardiac fibroblast activity.

Development & Formulation Notes

Stock Solutions & Handling

Prepare concentrated stocks (1–10 mM) in sterile water or DMSO. Maintain pH 6.5–7.5 for optimal stability; verify integrity via HPLC if stored for extended periods. Sterility assured via 0.22 µm filtration. Use low-binding tubes and carrier proteins (e.g., 0.1% BSA) for low-concentration assays.

Assay Design

Implement dose-response curves to determine cGMP induction, natriuretic response, or antifibrotic activity. Record matrix components, cell types, and reagent lots. Benchmark against native peptides (CNP, DNP) where applicable.

Combinations & Pathway Mapping

Suitable for use with diuretics (e.g., furosemide) or RAAS modulators to examine synergistic effects on cardiorenal function and preload dynamics.

Disclaimer

Cenderitide is supplied strictly for laboratory research purposes only. It is not a pharmaceutical, diagnostic, or veterinary product and is not intended for human or veterinary use. Handle according to institutional biosafety guidelines, using appropriate PPE. Dispose of materials per local regulations. All described properties pertain to preclinical research contexts. End-users assume responsibility for assay suitability and regulatory compliance.

Keywords

Cenderitide; dual pGC-A pGC-B activator; chimeric natriuretic peptide; CD-NP; heart failure research peptide; cGMP elevating peptide; antifibrotic natriuretic peptide; natriuresis diuresis peptide; GMP peptide; CAS 507289-11-4; research-use-only.

Packaging & Availability

• Standard Packs: 1 mg, 5 mg, 10 mg; custom sizes available

• Bulk/Wholesale: Multi-gram lots with batch reservation and scheduled delivery for large-scale studies

• Documentation: Each lot includes CoA, HPLC chromatogram, MS identity; extended QC available for audit purposes

Quality Assurance

Manufactured under GMP-compliant protocols. Routine analyses: identity (MS), purity (HPLC), residual solvents, water content, and appearance. Optional endotoxin and bioburden testing available upon request.

Custom Services

• Custom aliquoting & labeling to match your LIMS/ELN

• Formulation support for buffer composition and excipients

• Stability study design for storage and shipment conditions

• Experimental protocol design for heart failure and cardiorenal research